GAD2 and schizophrenia: Post-hoc analyses revealed that the expression of GAD2 full length was significantly decreased in schizophrenia patients (24% decrease, p = 7.05E-10) and bipolar disorder patients (22% decrease, p = 1.28E-02), with no changes in MDD patients (p = 5.92E-02) compared with controls.